Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
CA 2521648 C · Owner: Iwakami, Noboru · Inventors: Iwakami, Noboru; Kimura, Tatsuo; Saitoh, Akihito
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An alkyl ether derivative represented by the following general formula 1, (see formula 1) or its salt: wherein R1 and R2 represent each a substituent such as hydrogen, halogeno or alkyl; R3 represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and p is an integer of from 1 to 3; shows an effect of protecting retinal nerve cells and, therefore is , useful as a preventive and/or a remedy for retinal nerve diseases such as glaucoma, diabetic retinopathy retinal artery obstruction, retinal venous obstruction macular degeneration and retinopathy of prematurity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 15, 2004 and granted July 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 15, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 15, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.